Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmed Bilal Khalid

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Current Opinion in Oncology|March 6, 2026
Recent developments and outstanding challenges in germ cell tumorsAhmed Bilal Khalid, Tareq Salous
Journal of the National Comprehensive Cancer Network : JNCCN|December 12, 2022
Physician Awareness of Immune-Related Adverse Events of Immune Checkpoint InhibitorsAhmed Bilal Khalid, Gerardo Calderon, Shadia I Jalal, et al.
Frontiers in Immunology|February 28, 2022
Immunotherapy in Lung Cancer: Current Landscape and Future DirectionsHirva Mamdani, Sandro Matosevic, Ahmed Bilal Khalid, et al.
Frontiers in Oncology|December 6, 2024
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinomaAhmed Bilal Khalid, Christos Fountzilas, Heather N Burney, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|April 18, 2020
Knowledge, awareness, and practices of cervical cancer, its risk factors, screening, and prevention among women in Karachi, PakistanSamina Hirani, Sarah Khan, Sidra Akram, et al.
Journal for Immunotherapy of Cancer|March 6, 2024
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromesAmin H Nassar, Talal El Zarif, Ahmed Bilal Khalid, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Current Opinion in Oncology|March 6, 2026
Recent developments and outstanding challenges in germ cell tumorsAhmed Bilal Khalid, Tareq Salous
Journal of the National Comprehensive Cancer Network : JNCCN|December 12, 2022
Physician Awareness of Immune-Related Adverse Events of Immune Checkpoint InhibitorsAhmed Bilal Khalid, Gerardo Calderon, Shadia I Jalal, et al.
Frontiers in Immunology|February 28, 2022
Immunotherapy in Lung Cancer: Current Landscape and Future DirectionsHirva Mamdani, Sandro Matosevic, Ahmed Bilal Khalid, et al.
Frontiers in Oncology|December 6, 2024
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinomaAhmed Bilal Khalid, Christos Fountzilas, Heather N Burney, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|April 18, 2020
Knowledge, awareness, and practices of cervical cancer, its risk factors, screening, and prevention among women in Karachi, PakistanSamina Hirani, Sarah Khan, Sidra Akram, et al.
Journal for Immunotherapy of Cancer|March 6, 2024
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromesAmin H Nassar, Talal El Zarif, Ahmed Bilal Khalid, et al.
Pageof 1